Drug Targets in Hepatitis B Virus Infection

Stein, Lance L.; Loomba, Rohit
April 2009
Infectious Disorders - Drug Targets;Apr2009, Vol. 9 Issue 2, p105
Academic Journal
Hepatitis B virus infection (HBV) is a significant global health problem. Despite the success of universal hepatitis B vaccination in many countries, more than 350 million individuals worldwide are chronically infected and 15- 40% of those will develop cirrhosis and/or hepatocellular carcinoma if left untreated. Available therapies for chronic hepatitis B (CHB) infection are effective at decreasing viremia and improving measured clinical outcomes, however, no single therapy is optimal. As such, alternative drug therapies and the investigation of their role in the management of CHB are warranted. Significant improvements in the understanding of the HBV life cycle, viral genomics, and virus-host interactions continue to lead to the development of novel viral targets and immune modulators. Currently, two major classes of agents are utilized in CHB: the interferons and the nucleos(t)ide analogues. Each agent has individual advantages and drawbacks. The development of specific antiviral therapy has led to the emergence of HBV drug-resistant strains that has limited the long-term therapeutic potential of available agents. This necessitates the development of new agents that target both wild-type and drug-resistant strains. Further understanding of the basic mechanisms and clinical nuances of drug therapy is warranted. As most novel therapies are in the earliest stages of clinical development and testing, in the near future, treatment will continue to be long-term and likely involve the use of combination therapies to prevent viral resistance. In this review, we will highlight the HBV life cycle and genome, focusing in on current and potential novel antiviral drug targets as well as the benefits and clinical challenges with these therapies.


Related Articles

  • Interferon-Stimulated Gene 15 Conjugation Stimulates Hepatitis B Virus Production Independent of Type I Interferon Signaling Pathway In Vitro. Li, Yujia; Li, Shilin; Duan, Xiaoqiong; Chen, Yanzhao; Jiao, Baihai; Ye, Haiyan; Yao, Min; Chen, Limin // Mediators of Inflammation;10/27/2016, p1 

    Hepatitis B virus (HBV) is an important account of infectious hepatitis and interferon (IFN) remains one of the best treatment options. Activation of type I IFN signaling pathway leads to expressions of IFN-stimulated genes (ISGs) which play important roles in antiviral and immunomodulatory...

  • Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. Li Jiang; Li-Sheng Jiang; Nan-Sheng Cheng; Lu-Nan Yan; Levitsky, Josh; Razonable, Raymund R. // World Journal of Gastroenterology;5/28/2009, Vol. 15 Issue 20, p2489 

    Prophylactic strategies against hepatitis B virus (HBV) recurrence after liver transplantation (LT) are essential for patients with HBV-related disease. Before LT, lamivudine (LAM) was proposed to be down-graded from first- to second-line therapy. In contrast, adefovir dipivoxil (ADV) has been...

  • TRANSMITEREA PERINATALÄ‚ A VIRUSULUI HEPATITIC B. Florescu, Simin // Romanian Journal of Infectious Diseases;2009, Vol. 12 Issue 4, p234 

    Perinatal transmision of viral hepatitis B is the main way of transmission in the high endemic regions, with a prevalence of ≥8%. The age at which a person becomes infected with HBV is the main factor determining the outcome, and the development of chronic hepatitis B is frequent in...

  • New Drug Targets for Hepatitis C and Other Flaviviridae Viruses. Paula, Tuma; Pablo, Rivas; Eugenia, Vispo; Pablo, Barreiro; Sabino, Puente; Jos�, Medrano; Antonio, Madej�n; Dolores, Herrero M.; Pablo, Labarga; Javier, Garcia-Samaniego; Vincente, Soriano Vincente // Infectious Disorders - Drug Targets;Apr2009, Vol. 9 Issue 2, p133 

    The Flaviviridae family comprises the genus Flavivirus, Hepacivirus and Pestivirus. These viruses are responsible for considerable human and animal disease and mortality worldwide. Flaviviruses cause a range of acute febrile illnesses along with encephalitic or haemorrhagic diseases. Chronic...

  • INDUCTION OF HUMORAL IMMUNE RESPONSE USING HUMAN INTERFERON ALPHA 2B AND RECOMBINANT ANTI-HEPATITIS B VACCINE IN ASYMPTOMATIC CARRIER PATIENTS OF HEPATITIS B VIRUS. Torres, J. A. Santiesteban; Griego, A. González; González, A. Alerm; Acosta, J. Acosta; González, V. E.; Castillo, E. García; Montenegro, A.; De León, O. Ponce // Revista VacciMonitor (Vacunología y Temas Afines);Oct2002, Vol. 11 Issue 4, p1 

    The clinical consequences of Hepatitis B Virus (HBV) are extremely variables. Approximaltity 5-10 % of adults exposed to HBV and the 90 % of perinatally infect children develop a chronic infection. The nature of chronic infection is also variable. The Asymptomatic Carrier State (ASC) can have...

  • HEPATITIS B: LESSENING ITS GRIP? Magill-Lewis, Jillene // Drug Topics;8/21/2006, Vol. 150 Issue 16, pHSE11 

    The article reports on developments regarding the prevention of hepatitis B in the U.S. due to the introduction of new antiviral agents in the country. The number of new cases of hepatitis B has declined due to the vaccination of children and adolescents. Several programs were instituted in 2006...

  • Direct Ex Vivo Evaluation of Long-Lived Protective Antiviral Memory B Cell Responses against Hepatitis B Virus. Ward, Scott M.; Phalora, Prabhjeet; Bradshaw, Daniel; Leyendeckers, Heike; Klenerman, Paul // Journal of Infectious Diseases;9/15/2008, Vol. 198 Issue 6, p813 

    Background. The frequency of protective antiviral memory B cells after hepatitis B virus (HBV) vaccination is unknown. Methods. A novel 2-step immunomagnetic protocol to assess the ex vivo frequency of protective HBV surface antigen (HBsAg)-specific memory B cells was used. Results....

  • Interferon-γ Production Specific for Hepatitis B Virus Antigen by Intrahepatic T Lymphocytes in Patients with Acute and Chronic Hepatitis B. Kakumu, Shinichi; Ishikawa, Tetsuya; Wakita, Takaji; Voshioka, Kentaro; Takayanagi, Masahiro; Tahara, Hirofumi; Kusakabe, Atsuhiko // American Journal of Gastroenterology;Jan1994, Vol. 89 Issue 1, p92 

    Objectives: Studies were undertaken to determine whether intrahepatic lymphocytes have a greater cellular immune response specific for hepatitis B virus (HBV) antigen than peripheral blood lymphocytes in HBV- infected man. Methods: HB nucleocapsid anti-gen-stimulated...

  • Viral immunity: Arms convoy. Bordon, Yvonne // Nature Reviews Immunology;Aug2013, Vol. 13 Issue 8, p547 

    The article discusses the study that explores the promotion of antiviral immunity through the mechanisms of type 1 interferons (IFNs). It mentions the release of the type 1 IFNs in response to virus infection and in the promotion of gene expression. It adds that the hepatitis B virus (HBV)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics